20/145毫克的阿托瓦斯塔丁/芬诺纤维酸固剂组合和相应的单个成分之间的药理动力学比较
Seungri Lee1, Juyoung Khwarg1, Sungyeun Bae1
1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Clinical pharmacology in drug development
|March 10, 2026
概括
一种新的固定剂量组合 (FDC) 的阿托瓦斯塔丁和费诺纤维酸盐表明可比的药物动力学特征单个成分. 这种固定剂量组合提供了一个方便的治疗选择,用于管理失脂症.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物开发 药物开发
背景情况:
- 同时服用阿托瓦斯塔丁和费诺纤维酸盐在临床上对失脂症有益.
- 固定剂量组合 (FDCs) 改善了患者的坚持和方便.
- 评估FDC的药理动力学 (PK) 和安全性概况至关重要.
研究的目的:
- 为了比较20/145毫克阿托瓦斯/芬纤维酸固剂组合 (FDC) 与单个成分的药理动力学 (PKs) 和安全性.
- 评估FDC配方的生物等价性.
- 支持FDC作为治疗失脂症的方便替代品.
主要方法:
- 一个随机的,开放的,单剂量,完全复制的交叉研究设计.
- 36名参与者在两个序列中接受了FDC或单个组件.
- 用非分组方法和混合效应模型分析了药理动力学参数.
主要成果:
- 对阿托瓦斯塔丁和2-OH阿托瓦斯塔丁的最大血度和曲线下的面积的几何平均比率 (GMR) 处于生物等效限内.
- 纤维酸还显示了与GMR在公认范围内的可比的PK配置文件.
- 与单个组件相比,没有报告FDC的重大安全问题.
结论:
- 20/145毫克的阿托瓦斯塔丁/费诺纤维酸固定剂量组合 (FDC) 与单个药物的药理学特征相似.
- FDC配方与阿托瓦斯塔丁和费诺纤维酸盐分别使用具有生物等价性.
- 这种FDC代表了一种可行且方便的治疗选择,用于患有血脂不良的患者.
相关概念视频
Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Dosage Regimens: Partial Pharmacokinetic Parameters
245
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
245
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
418
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
418
Dosage Regimen: Individualization
250
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
250
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
76
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly...
76
Pharmacokinetics: Drug–Drug Interactions
586
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
586


